{"transactions":[{"id":1103934,"issuer":{"id":6983,"kind":"organization","name":"Cingulate Inc."},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2025-06-24T00:02:17.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2026 annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":4.14,"expiration_date":"2035-06-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001641172-25-016180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862150/000164117225016180/ownership.xml","form_type":"4"}},{"id":1480866,"issuer":{"id":6983,"kind":"organization","name":"Cingulate Inc."},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2024-06-13T23:59:43.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests on the one-year anniversary of the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":0.7,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001493152-24-023769","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224023769/ownership.xml","form_type":"4"}},{"id":1480865,"issuer":{"id":6983,"kind":"organization","name":"Cingulate Inc."},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2024-06-13T23:59:43.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":14750,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The stock option grant was approved by Cingulate Inc.'s board of directors on March 4, 2024, subject to stockholder approval of Amendment No.1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan (the \"Amendment\"). Cingulate's stockholders approved the Amendment on June 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The option was issued to the reporting person in lieu of cash retainer fees of $29,500."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests on the one-year anniversary of the date of grant."}],"balance_after":14750,"derivative":{"exercise_price":1.18,"expiration_date":"2034-03-04","underlying":"Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001493152-24-023769","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224023769/ownership.xml","form_type":"4"}},{"id":1480864,"issuer":{"id":6983,"kind":"organization","name":"Cingulate Inc."},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2024-06-13T23:59:43.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The stock option grant was approved by Cingulate Inc.'s board of directors on March 4, 2024, subject to stockholder approval of Amendment No.1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan (the \"Amendment\"). Cingulate's stockholders approved the Amendment on June 11, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as follows: 50% on the six-month anniversary of the date of grant and the remaining shares on the twelve-month anniversary of the date of grant."}],"balance_after":5000,"derivative":{"exercise_price":1.18,"expiration_date":"2034-03-04","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001493152-24-023769","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224023769/ownership.xml","form_type":"4"}},{"id":1592038,"issuer":{"id":6983,"kind":"organization","name":"Cingulate Inc."},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2024-03-06T23:00:48.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as follows: 50% on the six-month anniversary of the date of grant and the remaining shares on the twelve-month anniversary of the date of grant."}],"balance_after":5000,"derivative":{"exercise_price":1.18,"expiration_date":"2034-03-04","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001493152-24-009092","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224009092/ownership.xml","form_type":"4"}},{"id":2326881,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2022-03-17T16:15:44.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application (\"IND\") with the U.S. Food and Drug Administration (\"FDA\") for a New Chemical Entity (\"NCE\") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":1,"expiration_date":"2032-03-15","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001493152-22-007154","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249872/000149315222007154/ownership.xml","form_type":"4"}},{"id":2495022,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-11-24T16:05:24.000Z","date":"2021-11-24","kind":"purchase","acquired":true,"shares":5000,"price":2.02,"value":10100.0,"ownership":{"direct":true},"balance_after":39807,"source":{"system":"sec-edgar","filing":"0001493152-21-029828","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249872/000149315221029828/ownership.xml","form_type":"4"}},{"id":2590709,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-08-25T17:03:47.000Z","date":"2021-08-23","kind":"purchase","acquired":true,"shares":10406,"price":2.41,"value":25078.46,"ownership":{"direct":true},"balance_after":34807,"source":{"system":"sec-edgar","filing":"0001493152-21-021244","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249872/000149315221021244/ownership.xml","form_type":"4"}},{"id":2692927,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-05-27T17:31:15.000Z","date":"2021-05-26","kind":"purchase","acquired":true,"shares":7041,"price":3.55,"value":24995.55,"ownership":{"direct":true},"balance_after":312117,"source":{"system":"sec-edgar","filing":"0001493152-21-013101","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1249872/000149315221013101/ownership.xml","form_type":"4"}},{"id":2692926,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-05-27T17:31:15.000Z","date":"2021-05-24","kind":"purchase","acquired":true,"shares":7440,"price":3.38,"value":25147.2,"ownership":{"direct":true},"balance_after":305076,"source":{"system":"sec-edgar","filing":"0001493152-21-013101","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249872/000149315221013101/ownership.xml","form_type":"4"}},{"id":2763662,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-04-01T21:21:56.000Z","date":"2021-03-30","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. Subject to continued employment, the option vests as to 25% of the shares on March 30, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on April 30, 2022."}],"balance_after":250000,"derivative":{"exercise_price":4.61,"expiration_date":"2031-03-30","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001493152-21-007805","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249872/000149315221007805/ownership.xml","form_type":"4"}},{"id":3679483,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2019-02-01T16:02:16.000Z","date":"2019-01-31","kind":"purchase","acquired":true,"shares":185436,"price":0.23,"value":42650.28,"ownership":{"direct":true},"balance_after":297636,"source":{"system":"sec-edgar","filing":"0000905718-19-000097","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249872/000090571819000097/ownership.xml","form_type":"4"}},{"id":3694456,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2019-01-16T16:42:50.000Z","date":"2019-01-14","kind":"purchase","acquired":true,"shares":100000,"price":0.225,"value":22500.0,"ownership":{"direct":true},"balance_after":112200,"source":{"system":"sec-edgar","filing":"0000905718-19-000053","document":"cancer_form4jan142019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249872/000090571819000053/cancer_form4jan142019.xml","form_type":"4"}},{"id":3934506,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-05-14T16:08:29.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Amended and Restated Cancer Genetics, Inc. 2011 Equity Incentive Plan (the \"2011 Plan\"). The shares underlying the options shall become vested and exercisable over time and subject to satisfaction of certain performance conditions consistent with the Company's current business plans, provided that the optionee remains a services provider to the Company through each applicable vesting period. The exercise price is the closing price of a share of Common Stock as of the date of grant on the NASDAQ Capital Market in accordance with the terms of the 2011 Plan."}],"balance_after":350000,"derivative":{"exercise_price":0.89,"expiration_date":"2028-05-10","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000905718-18-000476","document":"cancergene_fm4may102018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249872/000090571818000476/cancergene_fm4may102018.xml","form_type":"4"}},{"id":4128399,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-12-18T08:19:04.000Z","date":"2017-12-15","kind":"purchase","acquired":true,"shares":12200,"price":1.995,"value":24339.0,"ownership":{"direct":true},"balance_after":12200,"source":{"system":"sec-edgar","filing":"0001349929-17-000098","document":"wf-form4_151360313084956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249872/000134992917000098/wf-form4_151360313084956.xml","form_type":"4"}},{"id":4424245,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":78223,"kind":"person","name":"ROBERTS JOHN A","position":1,"cik":"0001249872","reported_name":"ROBERTS JOHN A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-02-24T16:52:49.000Z","date":"2017-02-22","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest in 48 equal monthly installments commencing on the date of grant until fully vested, provided that the reporting person remains a service provider to Cancer Genetics, Inc. through each applicable vesting period."}],"balance_after":30000,"derivative":{"exercise_price":2.5,"expiration_date":"2027-02-22","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001349929-17-000017","document":"wf-form4_148797315614652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249872/000134992917000017/wf-form4_148797315614652.xml","form_type":"4"}}]}